Harvard Bioscience (HBIO, Financial) shares experienced a sharp decline of 5.68%, currently priced at $2.16 per share. Trading volume reached approximately 138,486 shares, with a turnover rate of 0.32% and a volatility of 5.24%.
Recent financial reports indicate that the company generated $21.97 million in revenue while incurring a net loss of $4.80 million, resulting in earnings per share of -$0.11. The company reported a gross profit of $11.43 million and currently holds a price-to-earnings ratio of -6.61. Analysts are optimistic, with two out of two providing a buy recommendation for the stock.
The medical device sector, where Harvard Bioscience operates, saw an overall decline of 1.46%. Within this sector, companies like Zentek Ltd., and Innovative Eyewear Inc. experienced significant gains, while Glucotrack, Inc., and Akoya Biosciences, Inc. exhibited high trading activity.
Harvard Bioscience specializes in developing, manufacturing, and selling scientific instruments that support drug development and life sciences research. The company operates in North America, Europe, and China, offering products under well-known brands and generating most of its revenue in the United States.
